Board of Directors

According to Saniona's Article of Associations, the Board of Directors shall consist of not less than three and not more than eight members. Currently, the Board of Directors consist of five members including the chairman.

 

 

J. Donald deBethizy (born 1950)

Chairman since 2018

Education and background: Ph.D. and M.Sc. in toxicology from Utah State University and a B.Sc. in biology from the University of Maryland. J. Donald deBethizy is also co-founder and former CEO of Targacept, Inc., an American biotech company listed on Nasdaq, 1997-2012, and CEO of Santaris Pharma A/S, from January to October 2014, when the company was sold to Roche Holdings.

Other ongoing assignments: Chairman in Albumix Ltd. and Saniona A/S. Board member in argenx N.V., Newron Pharmaceuticals SpA, Noxxon NV and Proterris, Inc. Member of management (direktion) of Albumin Holding ApS and White City Consulting ApS.

Previous assignments completed within the past five years: Executive Chairman of Contera Pharma A/S. Chairman of Novozymes Biopharma DK A/S and Rigontec GmbH. Board member of Asceneuron SA, Biosource Inc., Enbiotix Inc., LigoCyte Pharmaceuticals Inc., Serenova A/S (previously named Serendex Pharmaceuticals A/S) and Targacept Inc. CEO and group chief executive of Roche Innovation Center Copenhagen A/S (previously named Santaris Pharma A/S).

Independence: Independent in relation to both the Company and its management as well as major shareholders.

Holdings in Saniona: 217,625 warrants, in the warrant program 2018/2024.

 

 

Anna Ljung (born 1980)

Board member since 2018

Education and background: M.Sc. in Economics and Business Administration from Stockholm School of Economics. Current CEO of Moberg Pharma AB and previous experience from different positions as CFO at Athera Biotechnologies AB, Moberg Pharma AB and Lipopeptide AB as well as independent consultant within the field of technology licensing.

Other ongoing assignments: Chairman of Moberg Derma Incentives AB. Board member of Moberg Pharma 2019 and Saniona A/S. CEO of Moberg Pharma AB.

Previous assignments completed within the past five years: Board member of MPJ OTC AB. Deputy board member of Moberg Derma Incentives AB.

Independence: Independent in relation to both the Company and its management as well as major shareholders.

Holdings in Saniona: 4,000 warrants in the warrant program 2018/2024 and 4,000 warrants in the warrant program 2019/2023 and 77,000 warrants in the warrant program 2020/2024.

 

Carl Johan Sundberg (born 1958)

Board member since 2015 (board member of Saniona A/S since 2016)

Education and background: Medical degree and Ph.D. from Karolinska Institutet, Stockholm. Professor in molecular and applied exercise physiology at Karolinska Institutet. Co-founder of, and previous Investment Managerat, Karolinska Investment Fund - a EUR 60 million biomedicine venture capital fund. Head of research at the department of Bioentrepreneurship at Karolinska Institutet, member of the Royal Swedish Academy of Engineering Sciences, previous member and previous chairman of Swedish Professional Associations for Physical Activity and the foundation Forska!Sverige and member of the International Olympic Committee Medical Commission. Many years of experience from board work within the academy and the business community. Professor at the department of Physiology and Pharmacology at Karolinska Institutet. Head of the department of Learning, Informatics, Management and Ethics at Karolinska Institutet.

Other ongoing assignments: Board member of Arne Ljungqvist Anti-doping Foundation AB, Medkay Konsulting AB and Saniona A/S.

Previous assignments completed within the past five years: Board member of Cobra Biologics Holding AB, Hypercure Medical AB and Karolinska Development AB. Deputy board member of Symbiont Law AB. Partner in Medkay Konsulting HB.

Independence: Independent in relation to both the Company and its management as well as major shareholders.

Holdings in Saniona: 4,000 warrants in the warrant program 2018/2024 and 4,000 warrants in the warrant program 2019/2023 and 77,000 warrants in the warrant program 2020/2024.

 

Jørgen Drejer (born 1955)

Board member since 2014. Board member of Saniona A/S since 2012. CSO since 2020. Previous CEO of Saniona AB and Saniona A/S. Co-Founder of the company of Saniona A/S and Saniona AB.

Education and background: Ph.D. in neurobiology from the University of Copenhagen. One of the co-founders of NeuroSearch A/S and long operated as the Company's deputy CEO and head of research. Member of the Danish Academy of Engineering Science and previous member of the board of Danish Research Council for Independent Research. Author of more than 75 scientific articles.

Other ongoing assignments: Board member of Saniona A/S. Board member of 2CureX AB and 2CureX A/S

Previous assignments completed within the past five years: Chairman of Delta Reader A/S. Board member of Atonomics A/S, Azign Bioscience A/S, Ellegaard Göttingen Minipigs ApS, Force Technology and Monta Biosciences A/S. CEO of Saniona AB and Saniona A/S.

Independnce: Not independent in relation to the Company and its management but independent in relation to major shareholders.

Holdings in Saniona: 2,344,711 shares and 80,852 warrants of series TO 3 and 77,000 warrants in the warrant program 2020/2024.

 

Edward C. Saltzman (born 1955)

Board member since 2019

Education and background: Degree from New York University. Executive Chairman of Cello Health BioConsulting ("CHBC"), previously Defined Health, after having led the sale of Defined Health to Cello Health in 2017. CHBC is a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment. Edward C. Saltzman possesses a vast knowledge of the pharmaceutical and biotechnology industry accumulated over Defined Health's 25 years of consultancy to pharma, biotech, specialty pharma and investors. From this breadth and depth of experience, he provides guidance to CHBC's senior project leadership who work with clients across multiple therapeutic areas.

Other ongoing assignments: Chairman and member of management of Cello Health BioConsulting.

Previous assignments completed within the past five years: Board member of Vidac Pharmaceuticals Ltd.

Independence: Independent in relation to both the Company and its management as well as major shareholders.

Holdings in Saniona: 4,000 warrants in the warrant program 2019/2023 and 77,000 warrants in the warrant program 2020/2024.